Efficacy of Shufeng Jiedu Capsule combined with moxifloxacin in the treatment of community-acquired pneumonia

Objective To explore the efficacy of Shufeng Jiedu Capsule combined with moxifloxacin in the treatment of community-acquired pneumonia and its influence on serum C-reactive protein(CRP), procalcitonin(PCT)and white blood cell(WBC)count. Methods A total of 84 community acquired pneumonia patients were randomly divided into control group and combined group by using computer software, with 42 cases in each group. The control group was treated by moxifloxacin, while the combined group was given Shufeng Jiedu Capsule combined with moxifloxacin, the treatment course lasted for 7 days. Clinical symptoms time was observed, serum CRP, PCT, the WBC level and lung function related parameters such as forced expiratory volume in 1 second(FEV₁), ratio of FEV₁ to forced vital capacity(FEV₁/FVC), peak expiratory flow(PEF)before and after treatment of two groups were compared. Results The relief time of cough, chest pain, shortness of breath and rale in lung was significantly shorter in the combined group than those in the control group(P<0.05). Serum CRP, PCT and WBC levels in both groups decreased after treatment, and the above indexes in the combined group were significantly lower than those in the control group(P<0.05). The levels of FEV₁, FEV₁/FVC and PEF in both groups were increased after treatment, while the levels of FEV₁, FEV₁/FVC and PEF in the combined group were all significantly higher than those in the control group(P<0.05). Conclusion Shufeng Jiedu Capsule combined with moxifloxacin in the treatment of community acquired pneumonia has a good clinical effect, which can reduce serum CRP, PCT, WBC levels, and improve the pulmonary function of patients.